Novartis Ag (NVS) Receivables (2009 - 2026)
Novartis Ag (NVS) recorded Receivables of $9.64 billion in Q2 2026, up 6.4% from $9.06 billion a year earlier and up 2.7% from the prior quarter.
Powered by 
Analysis
Novartis Ag (NVS) Receivables (2009 - 2026) Analysis & Trends
At the end of FY2025, Novartis Ag reported Receivables of $8.94 billion, up 2.1% from FY2024.
- Annual Receivables has a five-year compound annual growth rate of -0.5% (FY2020 to FY2025).
- Across earlier years, Receivables came in at $8.75 billion in FY2024 (+4.7%), $8.36 billion in FY2023 (-7.4%), $9.02 billion in FY2022 (+2.6%) and $8.8 billion in FY2021 (-4.2%).
- The Q2 2026 figure is the highest quarterly Receivables since Q4 2018.
- On a year-over-year basis, Receivables has increased for eight consecutive quarters, with growth averaging 8.7% over the last eight quarters.
- Peak year-over-year performance for Receivables in the last five years was growth of 16.8% in Q3 2024, against a decline of 19.0% in Q3 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $9.39 billion (Q1 2026), $8.94 billion (Q4 2025) and $8.84 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 15.68 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 5.06 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 2.13 Bn |
| 10 | Bristol Myers Squibb | 127.55 Bn | 78.82 Bn | 9.25 Bn | 10.66 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.64 Bn |
| Mar 31, 2026 | 9.39 Bn |
| Dec 31, 2025 | 8.94 Bn |
| Sep 30, 2025 | 8.84 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Mar 31, 2025 | 8.60 Bn |
| Dec 31, 2024 | 8.75 Bn |
| Sep 30, 2024 | 7.97 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Mar 31, 2024 | 7.84 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Sep 30, 2023 | 6.82 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Mar 31, 2023 | 8.92 Bn |
| Dec 31, 2022 | 9.02 Bn |
| Sep 30, 2022 | 8.42 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Mar 31, 2022 | 8.41 Bn |
| Dec 31, 2021 | 8.80 Bn |
| Sep 30, 2021 | 8.38 Bn |
API Access
Novartis Ag Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=NVS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "NVS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=NVS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();